Beigene, LTD 10-Q quarterly reports

BeOne Medicines Ltd. announced a 30% increase in total global revenues for the second quarter of 2026, reaching $1.7 billion, driven by robust sales of BRUKINSA and other key products.

BeOne Medicines Ltd. announced a 35% increase in total revenues to $1.5 billion for the first quarter of 2026, driven by significant growth in BRUKINSA sales.

BeOne Medicines reported a significant increase in total revenues and product sales for Q3 and the first nine months of 2025, driven by strong global demand for BRUKINSA, leading to a substantial reduction in net losses.

BeOne Medicines reported a significant turnaround to net income in Q2 2025, driven by robust global sales of its oncology portfolio, particularly BRUKINSA.

BeiGene reports its first profitable quarter driven by strong Brukinsa sales and overall revenue growth.

BeiGene's third-quarter results show significant revenue growth, reaching $1 billion, driven by strong sales of BRUKINSA and a reduction in GAAP losses.

BeiGene's Q2 2024 results show a significant increase in revenue and a reduction in GAAP operating loss, achieving positive adjusted operating income.

BeiGene's Q1 2024 revenue surged to $752 million, fueled by an 82% increase in product revenue, particularly from BRUKINSA.